WO2012024530A3 - Therapeutic peptide-polymer conjugates, particles, compositions, and related methods - Google Patents
Therapeutic peptide-polymer conjugates, particles, compositions, and related methods Download PDFInfo
- Publication number
- WO2012024530A3 WO2012024530A3 PCT/US2011/048309 US2011048309W WO2012024530A3 WO 2012024530 A3 WO2012024530 A3 WO 2012024530A3 US 2011048309 W US2011048309 W US 2011048309W WO 2012024530 A3 WO2012024530 A3 WO 2012024530A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- polymer conjugates
- therapeutic peptide
- conjugates
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Polymers & Plastics (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112013003823A BR112013003823A2 (en) | 2010-08-20 | 2011-08-18 | therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
MX2013002051A MX2013002051A (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods. |
CA2808907A CA2808907A1 (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
AU2011291586A AU2011291586A1 (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
CN2011800403740A CN103079546A (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
EP11818802.8A EP2605797A2 (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
JP2013524987A JP5655147B2 (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions and related methods |
EA201390144A EA201390144A1 (en) | 2010-08-20 | 2011-08-18 | CONJUGATES THERAPEUTIC PEPTIDE POLYMER, PARTICLES, COMPOSITIONS AND RELATED METHODS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37577110P | 2010-08-20 | 2010-08-20 | |
US61/375,771 | 2010-08-20 | ||
US201161477827P | 2011-04-21 | 2011-04-21 | |
US61/477,827 | 2011-04-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012024530A2 WO2012024530A2 (en) | 2012-02-23 |
WO2012024530A3 true WO2012024530A3 (en) | 2012-05-03 |
Family
ID=45605679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/048309 WO2012024530A2 (en) | 2010-08-20 | 2011-08-18 | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
Country Status (10)
Country | Link |
---|---|
US (2) | US20120052097A1 (en) |
EP (1) | EP2605797A2 (en) |
JP (2) | JP5655147B2 (en) |
CN (1) | CN103079546A (en) |
AU (1) | AU2011291586A1 (en) |
BR (1) | BR112013003823A2 (en) |
CA (1) | CA2808907A1 (en) |
EA (1) | EA201390144A1 (en) |
MX (1) | MX2013002051A (en) |
WO (1) | WO2012024530A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2510942E (en) | 2005-04-07 | 2015-12-28 | Cardiorentis Ag | Use of natriuretic peptide for treating heart failure |
WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
KR102024957B1 (en) | 2011-11-09 | 2019-09-24 | 브리스톨-마이어스 스큅 컴퍼니 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
EP2841486B1 (en) * | 2012-04-23 | 2020-01-15 | NanoProteagen Ltd. | Polymeric nanoparticles and a process of preparation thereof |
US9636376B2 (en) * | 2012-09-11 | 2017-05-02 | Innopharma, Inc. | Stable compositions of peptide epoxy ketones |
CN105025918A (en) * | 2013-01-25 | 2015-11-04 | 卡迪欧伦蒂斯有限公司 | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications |
EP3052471B1 (en) | 2013-09-30 | 2023-06-21 | The University of Akron | Methods for post-fabrication functionalization of poly(ester ureas) |
US20170037234A1 (en) * | 2014-02-26 | 2017-02-09 | The Trustees Of Princeton University | Polymer nanoparticles |
US20150320988A1 (en) * | 2014-05-09 | 2015-11-12 | Ocusoft, Inc. | Systems, Methods, and Kits for Cleansing an Ocular Region |
US20160122713A1 (en) * | 2014-10-14 | 2016-05-05 | Medgenics Medical Israel Ltd. | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof |
BR112018000217A2 (en) * | 2015-07-15 | 2018-09-04 | Celator Pharmaceuticals Inc | improved nanoparticle distribution systems |
CN106924715A (en) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | terlipressin liposome and preparation method thereof |
US10039801B2 (en) | 2016-02-16 | 2018-08-07 | Strongbridge Ireland Limited | Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use |
JP7193448B2 (en) * | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | Depot system containing glatiramer acetate |
WO2018085407A1 (en) | 2016-11-02 | 2018-05-11 | Nanoproteagen | Polymeric nanoparticles |
WO2018175589A1 (en) * | 2017-03-22 | 2018-09-27 | The Regents Of The University Of California | Modified peptides and uses thereof for treating cancer |
MX2019010174A (en) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Glatiramer depot systems for treating progressive forms of multiple sclerosis. |
US11214672B2 (en) | 2018-01-19 | 2022-01-04 | The Trustees Of Princeton University | Hybrid polymer-inorganic nanocolloids and methods of making them |
US20220193210A1 (en) | 2018-02-02 | 2022-06-23 | Danmarks Tekniske Universitet | Therapeutics for autoimmune kidney disease: synthetic antigens |
WO2022108870A1 (en) * | 2020-11-17 | 2022-05-27 | 9 Meters Biopharma, Inc. | Compositions and methods for treating pulmonary fibrosis |
WO2023141278A2 (en) * | 2022-01-20 | 2023-07-27 | The University Of North Carolina At Chapel Hill | Composite particle formulations and applications thereof |
CN114835888B (en) * | 2022-04-18 | 2023-08-08 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Tumor in-situ assembled nano-carrier system, drug carrying system and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US20040142887A1 (en) * | 2002-07-10 | 2004-07-22 | Chengji Cui | Antigen-polymer compositions |
WO2010046681A1 (en) * | 2008-10-24 | 2010-04-29 | Fujifilm Manufacturing Europe Bv | Nanoparticles |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
EP0712421A1 (en) * | 1993-07-23 | 1996-05-22 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
KR19990085365A (en) * | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
CA2338345A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Encapsulation of water soluble peptides |
US8137699B2 (en) * | 2002-03-29 | 2012-03-20 | Trustees Of Princeton University | Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use |
AU2005269800B8 (en) * | 2004-07-19 | 2011-12-01 | Celator Pharmaceuticals, Inc. | Particulate constructs for release of active agents |
WO2007038763A1 (en) * | 2005-09-28 | 2007-04-05 | The Trustees Of The University Of Pennsylvania | Self-assembled biodegradable polymersomes |
US20070071790A1 (en) * | 2005-09-28 | 2007-03-29 | Northwestern University | Biodegradable nanocomposites with enhance mechanical properties for soft tissue |
-
2011
- 2011-08-18 EA EA201390144A patent/EA201390144A1/en unknown
- 2011-08-18 CN CN2011800403740A patent/CN103079546A/en active Pending
- 2011-08-18 JP JP2013524987A patent/JP5655147B2/en not_active Expired - Fee Related
- 2011-08-18 MX MX2013002051A patent/MX2013002051A/en unknown
- 2011-08-18 WO PCT/US2011/048309 patent/WO2012024530A2/en active Application Filing
- 2011-08-18 EP EP11818802.8A patent/EP2605797A2/en not_active Withdrawn
- 2011-08-18 AU AU2011291586A patent/AU2011291586A1/en not_active Abandoned
- 2011-08-18 CA CA2808907A patent/CA2808907A1/en not_active Abandoned
- 2011-08-18 US US13/212,971 patent/US20120052097A1/en not_active Abandoned
- 2011-08-18 BR BR112013003823A patent/BR112013003823A2/en not_active IP Right Cessation
-
2013
- 2013-03-28 US US13/852,738 patent/US20140135254A1/en not_active Abandoned
-
2014
- 2014-11-21 JP JP2014236423A patent/JP2015052012A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US20040142887A1 (en) * | 2002-07-10 | 2004-07-22 | Chengji Cui | Antigen-polymer compositions |
WO2010046681A1 (en) * | 2008-10-24 | 2010-04-29 | Fujifilm Manufacturing Europe Bv | Nanoparticles |
Also Published As
Publication number | Publication date |
---|---|
CN103079546A (en) | 2013-05-01 |
WO2012024530A2 (en) | 2012-02-23 |
EP2605797A2 (en) | 2013-06-26 |
JP2015052012A (en) | 2015-03-19 |
US20140135254A1 (en) | 2014-05-15 |
AU2011291586A1 (en) | 2013-03-07 |
BR112013003823A2 (en) | 2016-06-28 |
EA201390144A1 (en) | 2013-06-28 |
JP2013536198A (en) | 2013-09-19 |
US20120052097A1 (en) | 2012-03-01 |
MX2013002051A (en) | 2013-06-28 |
CA2808907A1 (en) | 2012-02-23 |
JP5655147B2 (en) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
MX2011010390A (en) | Polymer-agent conjugates, particles, compositions, and related methods of use. | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MY157124A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
WO2011082273A3 (en) | Substituted pyrrolo-aminopyrimidine compounds | |
TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
UA109464C2 (en) | Spiro-oxindoles as mdm2 antagonists | |
WO2011082267A8 (en) | Substituted triazolo-pyrazine compounds | |
WO2012118812A3 (en) | Substituted 6,5-fused bicyclic heteroaryl compounds | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
MX339239B (en) | Anti-cd40 antibodies and methods of use. | |
WO2014062720A3 (en) | Methods of treating cancer | |
JOP20110402B1 (en) | Anti-cd38 antibodies | |
JO3776B1 (en) | PHARMACEUTICAL COMBINATIONS of a CDK4/6 inhibitor and B-Raf inhibitor | |
PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
WO2011123678A3 (en) | Substituted benzo-pyrido-triazolo-diazepine compounds | |
MY191932A (en) | Chitosan-derived compositions | |
WO2011082268A3 (en) | Substituted naphthalenyl-pyrimidine compounds | |
MX2013013649A (en) | Quinone compounds for treating ape1 mediated diseases. | |
WO2012061342A3 (en) | Substituted benzo-imidazo-pyrido-diazepine compounds | |
WO2011082271A3 (en) | Substituted triazolo-pyrimidine compounds | |
PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
WO2012088491A3 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | |
WO2013013075A3 (en) | Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180040374.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11818802 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2013524987 Country of ref document: JP Kind code of ref document: A Ref document number: 2808907 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011818802 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011818802 Country of ref document: EP Ref document number: 201390144 Country of ref document: EA Ref document number: MX/A/2013/002051 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2011291586 Country of ref document: AU Date of ref document: 20110818 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013003823 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013003823 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130219 |